According to a recent LinkedIn post from Glooko, the company is positioning its diabetes and glycemic management platforms alongside EndoTool from Monarch Medical Technologies, a Glooko company, as part of a more integrated care ecosystem. The post highlights alignment with the American Diabetes Association’s 2026 Standards of Care in Diabetes, which encourage linking inpatient and outpatient data streams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that tighter integration of these platforms could support diabetes management at scale across care settings, potentially increasing Glooko’s relevance to large health systems. For investors, this emphasis on standards-driven interoperability may signal a strategic focus on enterprise adoption and recurring software revenues, while also strengthening Glooko’s competitive position in the digital diabetes and glycemic management market.